84 results on '"Ludolph, Albert C."'
Search Results
2. TUBA4A downregulation as observed in ALS post-mortem motor cortex causes ALS-related abnormalities in zebrafish.
- Author
-
Van Schoor, Evelien, Strubbe, Dufie, Braems, Elke, Weishaupt, Jochen, Ludolph, Albert C., Van Damme, Philip, Rudolf, Dietmar, Thal, Bercier, Valérie, and Van Den Bosch, Ludo
- Subjects
AMYOTROPHIC lateral sclerosis ,MOTOR neuron diseases ,MOTOR cortex ,BRACHYDANIO ,POSTMORTEM changes ,SYNAPTIC vesicles ,STARTLE reaction ,POST-translational modification - Abstract
Disease-associated variants of TUBA4A (alpha-tubulin 4A) have recently been identified in familial ALS. Interestingly, a downregulation of TUBA4A protein expression was observed in familial as well as sporadic ALS brain tissue. To investigate whether a decreased TUBA4A expression could be a driving factor in ALS pathogenesis, we assessed whether TUBA4A knockdown in zebrafish could recapitulate an ALS-like phenotype. For this, we injected an antisense oligonucleotide morpholino in zebrafish embryos targeting the zebrafish TUBA4A orthologue. An antibody against synaptic vesicle 2 was used to visualize motor axons in the spinal cord, allowing the analysis of embryonic ventral root projections. Motor behavior was assessed using the touch-evoked escape response. In post-mortem ALS motor cortex, we observed reduced TUBA4A levels. The knockdown of the zebrafish TUBA4A orthologue induced a motor axonopathy and a significantly disturbed motor behavior. Both phenotypes were dose-dependent and could be rescued by the addition of human wild-type TUBA4A mRNA. Thus, TUBA4A downregulation as observed in ALS post-mortem motor cortex could be modeled in zebrafish and induced a motor axonopathy and motor behavior defects reflecting a motor neuron disease phenotype, as previously described in embryonic zebrafish models of ALS. The rescue with human wild-type TUBA4A mRNA suggests functional conservation and strengthens the causal relation between TUBA4A protein levels and phenotype severity. Furthermore, the loss of TUBA4A induces significant changes in post-translational modifications of tubulin, such as acetylation, detyrosination and polyglutamylation. Our data unveil an important role for TUBA4A in ALS pathogenesis, and extend the relevance of TUBA4A to the majority of ALS patients, in addition to cases bearing TUBA4A mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Skeletal muscle in amyotrophic lateral sclerosis.
- Author
-
Shefner, Jeremy M, Musaro, Antonio, Ngo, Shyuan T, Lunetta, Christian, Steyn, Frederik J, Robitaille, Richard, Carvalho, Mamede De, Rutkove, Seward, Ludolph, Albert C, and Dupuis, Luc
- Subjects
AMYOTROPHIC lateral sclerosis ,SKELETAL muscle ,MOTOR neuron diseases ,MUSCLE weakness ,MOTOR neurons ,NEMALINE myopathy - Abstract
Amyotrophic lateral sclerosis (ALS), the major adult-onset motor neuron disease, has been viewed almost exclusively as a disease of upper and lower motor neurons, with muscle changes interpreted as a consequence of the progressive loss of motor neurons and neuromuscular junctions. This has led to the prevailing view that the involvement of muscle in ALS is only secondary to motor neuron loss. Skeletal muscle and motor neurons reciprocally influence their respective development and constitute a single functional unit. In ALS, multiple studies indicate that skeletal muscle dysfunction might contribute to progressive muscle weakness, as well as to the final demise of neuromuscular junctions and motor neurons. Furthermore, skeletal muscle has been shown to participate in disease pathogenesis of several monogenic diseases closely related to ALS. Here, we move the narrative towards a better appreciation of muscle as a contributor of disease in ALS. We review the various potential roles of skeletal muscle cells in ALS, from passive bystanders to active players in ALS pathophysiology. We also compare ALS to other motor neuron diseases and draw perspectives for future research and treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Guideline "Motor neuron diseases" of the German Society of Neurology (Deutsche Gesellschaft für Neurologie).
- Author
-
Petri, Susanne, Grehl, Torsten, Grosskreutz, Julian, Hecht, Martin, Hermann, Andreas, Jesse, Sarah, Lingor, Paul, Löscher, Wolfgang, Maier, André, Schoser, Benedikt, Weber, Marcus, and Ludolph, Albert C.
- Subjects
MOTOR neuron diseases ,AMYOTROPHIC lateral sclerosis ,MOTOR neurons ,SPINAL cord ,MOVEMENT disorders ,BRAIN stem - Abstract
Introduction: In 2021, the Deutsche Gesellschaft für Neurology published a new guideline on diagnosis and therapy of motor neuron disorders. Motor neuron disorders affect upper motor neurons in the primary motor cortex and/or lower motor neurons in the brain stem and spinal cord. The most frequent motor neuron disease amyotrophic lateral sclerosis (ALS) is a rapidly progressive disease with an average life expectancy of 2–4 years with a yearly incidence of 3.1/100,000 in Central Europe (Rosenbohm et al. in J Neurol 264(4):749–757, 2017. https://doi.org/10.1007/s00415-017-8413-3). It is considered a rare disease mainly due to its low prevalence as a consequence of short disease duration. Recommendations: These guidelines comprise recommendations regarding differential diagnosis, neuroprotective therapies and multidisciplinary palliative care including management of respiration and nutrition as well as provision of assistive devices and end-of-life situations. Conclusion: Diagnostic and therapeutic guidelines are necessary due the comparatively high number of cases and the aggressive disease course. Given the low prevalence and the severe impairment of patients, it is often impossible to generate evidence-based data so that ALS guidelines are partially dependent on expert opinion. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. DNA Methylation Analysis in Monozygotic Twins Discordant for ALS in Blood Cells.
- Author
-
Yazar, Volkan, Ruf, Wolfgang P, Knehr, Antje, Günther, Kornelia, Ammerpohl, Ole, Danzer, Karin M, and Ludolph, Albert C
- Subjects
DNA analysis ,METHYLATION ,DNA methylation ,BLOOD cells ,MOTOR neuron diseases ,TWIN studies - Abstract
ALS is a fatal motor neuron disease that displays a broad variety of phenotypes ranging from early fatal courses to slowly progressing and rather benign courses. Such divergence can also be seen in genetic ALS cases with varying phenotypes bearing specific mutations, suggesting epigenetic mechanisms like DNA methylation act as disease modifiers. However, the epigenotype dictated by, in addition to other mechanisms, DNA methylation is also strongly influenced by the individual's genotype. Hence, we performed a DNA methylation study using EPIC arrays on 7 monozygotic (MZ) twin pairs discordant for ALS in whole blood, which serves as an ideal model for eliminating the effects of the genetic-epigenetic interplay to a large extent. We found one CpG site showing intra-pair hypermethylation in the affected co-twins, which maps to the Glutamate Ionotropic Receptor Kainate Type Subunit 1 gene (GRIK1). Additionally, we found 4 DMPs which were subsequently confirmed using 2 different statistical approaches. Differentially methylated regions or blocks could not be detected within the scope of this work. In conclusion, we revealed that despite a low sample size, monozygotic twin studies discordant for the disease can bring new insights into epigenetic processes in ALS, pointing to new target loci for further investigations. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Sequential alterations in diffusion metrics as correlates of disease severity in amyotrophic lateral sclerosis.
- Author
-
Müller, Hans-Peter, Behler, Anna, Münch, Maximilian, Dorst, Johannes, Ludolph, Albert C., and Kassubek, Jan
- Subjects
AMYOTROPHIC lateral sclerosis ,DIFFUSION tensor imaging ,PYRAMIDAL tract ,WHITE matter (Nerve tissue) ,MOTOR neuron diseases - Abstract
Background and objective: The neuropathology of amyotrophic lateral sclerosis (ALS) follows a regional distribution pattern in the brain with four stages. Using diffusion tensor imaging (DTI), this pattern can be translated into a tract-based staging scheme to assess cerebral progression in vivo. This study investigates the association between the sequential alteration pattern and disease severity in patients with ALS. Methods: DTI data of 325 patients with ALS and 130 healthy controls were analyzed in a tract of interest (TOI)-based approach. Patients were categorized according to their ALS-FRS-R scores into groups with declining functionality. The fractional anisotropy (FA) values in the tracts associated with neuropathological stages were group-wise compared with healthy controls. Results: The FA in the tracts associated with ALS stages showed a decrease which could be related to the disease severity stratification, i.e., at the group level, the lower the ALS-FRS-R of the categorized patient group, the higher was the effect size of the stage-related tract. In the patient group with the highest ALS-FRS-R, Cohen's d showed a medium effect size in the corticospinal tract and small effect sizes in the other stage-related tracts. Overall, the lower the ALS-FRS-R of the categorized patient group the higher was the effect size of the comparison with healthy controls. Conclusion: The progression of white matter alterations across tracts according to the model of sequential tract involvement is associated with clinical disease severity in patients with ALS, suggesting the use of staging-based DTI as a technical marker for disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Glial fibrillary acidic protein in cerebrospinal fluid of patients with spinal muscular atrophy.
- Author
-
Freigang, Maren, Steinacker, Petra, Wurster, Claudia D., Schreiber-Katz, Olivia, Osmanovic, Alma, Petri, Susanne, Koch, Jan C., Rostásy, Kevin, Huss, André, Tumani, Hayrettin, Winter, Benedikt, Falkenburger, Björn, Ludolph, Albert C., Otto, Markus, Hermann, Andreas, and Günther, René
- Subjects
GLIAL fibrillary acidic protein ,SPINAL muscular atrophy ,CEREBROSPINAL fluid ,MOTOR neuron diseases - Abstract
Objective: Activated astroglia is involved in the pathophysiology of neurodegenerative diseases and has also been described in animal models of spinal muscular atrophy (SMA). Given the urgent need of biomarkers for treatment monitoring of new RNA-modifying and gene replacement therapies in SMA, we examined glial fibrillary acidic protein concentrations in cerebrospinal fluid (cGFAP) as a marker of astrogliosis in SMA. Methods: 58 adult patients and 21 children with genetically confirmed 5q-associated SMA from four German motor neuron disease specialist care centers and 30 age- and sex-matched controls were prospectively included in this study. cGFAP was measured and correlated to motor performance and disease severity. Additionally, we compared cGFAP with neurofilament light chain concentrations in cerebrospinal fluid (cNfL). Results: cGFAP concentrations did not differ from controls but showed higher levels in more severely affected patients after adjustment for patients' age. Normalized cNfL values were associated with disease severity. Within 14 months of nusinersen treatment, cGFAP concentrations did not change, while cNfL decreased significantly. Interpretation: cGFAP is not an outstanding biomarker in SMA, but might support the hypothesis that glial activation is involved in SMA pathology. Unlike previously suggested, cNfL may be a promising biomarker also in adult patients with SMA, which should be subject to further investigations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Increased pyroptosis activation in white matter microglia is associated with neuronal loss in ALS motor cortex.
- Author
-
Van Schoor, Evelien, Ospitalieri, Simona, Moonen, Sebastiaan, Tomé, Sandra O., Ronisz, Alicja, Ok, Orkun, Weishaupt, Jochen, Ludolph, Albert C., Van Damme, Philip, Van Den Bosch, Ludo, and Thal, Dietmar Rudolf
- Subjects
MOTOR neuron diseases ,WHITE matter (Nerve tissue) ,AMYOTROPHIC lateral sclerosis ,MOTOR cortex ,PYROPTOSIS ,MOTOR neurons ,PYRIN (Protein) - Abstract
Amyotrophic lateral sclerosis (ALS) is characterized by the degeneration of motor neurons in the motor cortex, brainstem, and spinal cord. Although ALS is considered a motor neuron disorder, neuroinflammation also plays an important role. Recent evidence in ALS disease models indicates activation of the inflammasome and subsequent initiation of pyroptosis, an inflammatory type of cell death. In this study, we determined the expression and distribution of the inflammasome and pyroptosis effector proteins in post-mortem brain and spinal cord from ALS patients (n = 25) and controls (n = 19), as well as in symptomatic and asymptomatic TDP-43
A315T transgenic and wild-type mice. Furthermore, we evaluated its correlation with the presence of TDP-43 pathological proteins and neuronal loss. Expression of the NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome, pyroptosis effector protein cleaved Gasdermin D (GSDMD), and IL-18 was detected in microglia in human ALS motor cortex and spinal cord, indicative of canonical inflammasome-triggered pyroptosis activation. The number of cleaved GSDMD-positive precentral white matter microglia was increased compared to controls and correlated with a decreased neuronal density in human ALS motor cortex. Neither of this was observed in the spinal cord. Similar results were obtained in TDP-43A315T mice, where microglial pyroptosis activation was significantly increased in the motor cortex upon symptom onset, and correlated with neuronal loss. There was no significant correlation with the presence of TDP-43 pathological proteins both in human and mouse tissue. Our findings emphasize the importance of microglial NLRP3 inflammasome-mediated pyroptosis activation for neuronal degeneration in ALS and pave the way for new therapeutic strategies counteracting motor neuron degeneration in ALS by inhibiting microglial inflammasome/pyroptosis activation. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. Increased NF-L levels in the TDP-43G298S ALS mouse model resemble NF-L levels in ALS patients.
- Author
-
Buck, Eva, Oeckl, Patrick, Grozdanov, Veselin, Bopp, Verena, Kühlwein, Julia K., Ruf, Wolfgang P., Wiesner, Diana, Roselli, Francesco, Weishaupt, Jochen H., Ludolph, Albert C., Otto, Markus, and Danzer, Karin M.
- Subjects
MOTOR neuron diseases ,AMYOTROPHIC lateral sclerosis ,LABORATORY mice ,ANIMAL disease models - Abstract
Together, the present study demonstrates that ALS TDP-43 SP G298S sp mice recapitulate elevated serum NF-L levels as seen in ALS patients. Since we saw larger neurons in TDP-43 SP G298S sp mice already at 2 months of age we speculate that this type of MNs is highly vulnerable in ALS building the basis for MN degeneration already at this early time point. Elevated levels of neurofilament light chain (NF-L) in CSF and blood are linked to the presymptomatic and symptomatic phase of patients suffering from amyotrophic lateral sclerosis (ALS). [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
10. Involvement of cortico-efferent tracts in flail arm syndrome: a tract-of-interest-based DTI study.
- Author
-
Rosenbohm, Angela, Del Tredici, Kelly, Braak, Heiko, Huppertz, Hans-Jürgen, Ludolph, Albert C., Müller, Hans-Peter, and Kassubek, Jan
- Subjects
DIFFUSION tensor imaging ,MOTOR neuron diseases ,AMYOTROPHIC lateral sclerosis ,WHITE matter (Nerve tissue) ,SYNDROMES ,FRONTOTEMPORAL lobar degeneration - Abstract
Background: Flail arm syndrome is a restricted phenotype of motor neuron disease that is characterized by progressive, predominantly proximal weakness and atrophy of the upper limbs. Objective: The study was designed to investigate specific white matter alterations in diffusion tensor imaging (DTI) data from flail arm syndrome patients using a hypothesis-guided tract-of-interest-based approach to identify in vivo microstructural changes according to a neuropathologically defined amyotrophic lateral sclerosis (ALS)-related pathology of the cortico-efferent tracts. Methods: DTI-based white matter mapping was performed both by an unbiased voxel-wise statistical comparison and by a hypothesis-guided tract-wise analysis of fractional anisotropy (FA) maps according to the neuropathological ALS-propagation pattern for 43 flail arm syndrome patients vs 43 'classical' ALS patients vs 40 matched controls. Results: The analysis of white matter integrity demonstrated regional FA reductions for the flail arm syndrome group predominantly along the CST. In the tract-specific analysis according to the proposed sequential cerebral pathology pattern of ALS, the flail arm syndrome patients showed significant alterations of the specific tract systems that were identical to 'classical' ALS if compared to controls. Conclusions: The DTI study including the tract-of-interest-based analysis showed a microstructural involvement pattern in the brains of flail arm syndrome patients, supporting the hypothesis that flail arm syndrome is a phenotypical variant of ALS. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Dipeptide repeat protein and TDP-43 pathology along the hypothalamic–pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases.
- Author
-
Dedeene, Lieselot, Van Schoor, Evelien, Ospitalieri, Simona, Ronisz, Alicja, Weishaupt, Jochen H., Otto, Markus, Ludolph, Albert C., Scheuerle, Angelika, Vandenberghe, Rik, Van Damme, Philip, Poesen, Koen, and Thal, Dietmar Rudolf
- Subjects
PITUITARY dwarfism ,HYPOTHALAMUS ,ANTERIOR pituitary gland ,SOMATOMEDIN ,PATHOLOGY ,FRONTOTEMPORAL lobar degeneration ,SOMATOTROPIN ,MOTOR neuron diseases - Published
- 2020
- Full Text
- View/download PDF
12. Deficits in verbal fluency in presymptomatic mutation gene carriers-a developmental disorder.
- Author
-
Lulé, Dorothée E., Müller, Hans-Peter, Finsel, Julia, Weydt, Patrick, Knehr, Antje, Winroth, Ivar, Andersen, Peter, Weishaupt, Jochen, Uttner, Ingo, Kassubek, Jan, and Ludolph, Albert C.
- Subjects
GENETIC mutation ,FRONTOTEMPORAL lobar degeneration ,BEHAVIOR ,SENIOR housing ,MOTOR neuron diseases ,COGNITION ,MEMORY ,EXECUTIVE function ,BRAIN ,RESEARCH ,RESEARCH methodology ,LANGUAGE & languages ,MAGNETIC resonance imaging ,CASE-control method ,MEDICAL cooperation ,EVALUATION research ,NEUROPSYCHOLOGICAL tests ,COMPARATIVE studies ,SYMPTOMS ,AMYOTROPHIC lateral sclerosis ,SPATIAL behavior ,FRONTOTEMPORAL dementia ,LONGITUDINAL method - Abstract
Background: A mutation in C9orf72 constitute a cross-link between amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD). At clinical manifestation, both patient groups may present with either cognitive impairment of predominantly behaviour or language (in FTD) or motor dysfunctions (in ALS).Methods: In total, 36 non-symptomatic mutation carriers from ALS or FTD families were examined, including 21 subjects with C9orf72 and 15 with SOD1 mutations. Data were compared with 91 age-matched, education-matched and gender-matched healthy subjects (56 were first-degree relatives from ALS or FTD families, 35 with no known family history of ALS/FTD). MRI scanning for diffusion tensor imaging was performed to map fractional anisotropy (FA). Subjects performed an extensive neuropsychological assessment to address verbal fluency, language, executive, memory and visuospatial function. Measurements were repeated after 12 months.Results: C9orf72 expansion carriers performed significantly worse in verbal fluency and non-verbal memory and presented with distinct alterations in structural white matter integrity indicated by lower FA values in inferior and orbitofrontal cortical areas compared with carriers of SOD1 mutations or healthy subjects. Loss of structural integrity was associated with decreased verbal fluency performance. White matter alterations and cognitive performance showed no changes over 12 months in all subjects.Discussion: Reduced verbal fluency performance seems to be a distinct clinical feature of C9orf72 carriers before symptomatic disease onset without evidence for change over time in our cohort. The results support the emerging hypothesis of a general disorder in development in addition to neurodegeneration in C9orf72 carriers. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
13. Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis.
- Author
-
Ludolph, Albert C., Dorst, Johannes, Dreyhaupt, Jens, Weishaupt, Jochen H., Kassubek, Jan, Weiland, Ulrike, Meyer, Thomas, Petri, Susanne, Hermann, Andreas, Emmer, Alexander, Grosskreutz, Julian, Grehl, Torsten, Zeller, Daniel, Boentert, Matthias, Schrank, Bertold, Prudlo, Johannes, Winkler, Andrea S., Gorbulev, Stanislav, Roselli, Francesco, and Schuster, Joachim
- Subjects
- *
AMYOTROPHIC lateral sclerosis , *MOTOR neuron diseases , *NUTRITION , *WEIGHT loss , *DIET , *RANDOMIZED controlled trials , *SURVIVAL analysis (Biometry) , *BLIND experiment , *RILUZOLE , *NEUROPROTECTIVE agents , *RESEARCH funding , *COMBINED modality therapy , *STATISTICAL sampling - Abstract
Objective: Weight loss has been identified as a negative prognostic factor in amyotrophic lateral sclerosis, but there is no evidence regarding whether a high-caloric diet increases survival. Therefore, we sought to evaluate the efficacy of a high-caloric fatty diet (HCFD) for increasing survival.Methods: A 1:1 randomized, placebo-controlled, parallel-group, double-blinded trial (LIPCAL-ALS study) was conducted between February 2015 and September 2018. Patients were followed up at 3, 6, 9, 12, 15, and 18 months after randomization. The study was performed at 12 sites of the clinical and scientific network of German motor neuron disease centers (ALS/MND-NET). Eligible patients were randomly assigned (1:1) to receive either HCFD (405kcal/day, 100% fat) or placebo in addition to riluzole (100mg/day). The primary endpoint was survival time, defined as time to death or time to study cutoff date.Results: Two hundred one patients (80 female, 121 male, age = 62.4 ± 10.8 years) were included. The confirmatory analysis of the primary outcome survival showed a survival probability of 0.39 (95% confidence interval [CI] = 0.27-0.51) in the placebo group and 0.37 (95% CI = 0.25-0.49) in the HCFD group, both after 28 months (point in time of the last event). The hazard ratio was 0.97, 1-sided 97.5% CI = -∞ to 1.44, p = 0.44.Interpretation: The results provide no evidence for a life-prolonging effect of HCFD for the whole amyotrophic lateral sclerosis population. However, post hoc analysis revealed a significant survival benefit for the subgroup of fast-progressing patients. ANN NEUROL 2020;87:206-216. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
14. Story of the ALS-FTD continuum retold: rather two distinct entities.
- Author
-
Lulé, Dorothée E., Aho-Özhan, Helena E. A., Vázquez, Cynthia, Weiland, Ulrike, Weishaupt, Jochen H., Otto, Markus, Anderl-Straub, Sarah, Semler, Elisa, Uttner, Ingo, and Ludolph, Albert C.
- Subjects
APATHY ,FRONTOTEMPORAL lobar degeneration ,SYMPATHY ,AMYOTROPHIC lateral sclerosis ,MOTOR neuron diseases - Abstract
Objective: To determine the evolution and profile of cognitive and behavioural deficits in amyotrophic lateral sclerosis (ALS) and behavioural variant frontotemporal dementia (bvFTD) to disentangle the development of FTD in ALS and vice versa.Methods: In a prospective design, cognitive and behavioural profiles of 762 patients with motor predominant ALS (flail arm/leg syndrome, primary lateral sclerosis, pseudobulbar palsy, ALS) and behavioural predominant FTD (bvFTD, ALS-FTD) were determined and caregivers of patients with ALS were asked on the evolution of behavioural symptoms. Data were compared with 49 healthy controls. Cognition was measured with the Edinburgh Cognitive and Behavioral ALS Screen.Results: Evolution and features of cognitive profile of patients with motor predominant ALS were distinctly different from patients with behavioural FTD with regard to number and degree of affected cognitive domains. Also, in ALS mostly minus symptoms evolved after physical symptom onset whereas in ALS-FTD plus and minus symptoms were reported with an onset before physical degradation.Conclusion: Evolution of cognitive and behavioural profile in patients with motor predominant ALS is distinctly different from those psychocognitive findings in patients with behavioural variant dementia. This may support the hypothesis that (possibly genetic) triggers decide in the preclinical phase on either motor or psychocognitive phenotypes. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
15. Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme.
- Author
-
Meyer, Thomas, Kettemann, Dagmar, Maier, André, Grehl, Torsten, Weyen, Ute, Grosskreutz, Julian, Steinbach, Robert, Norden, Jenny, George, Annette, Hermann, Andreas, Guenther, René, Petri, Susanne, Schreiber-Katz, Olivia, Dorst, Johannes, Ludolph, Albert C., Walter, Bertram, Münch, Christoph, and Spittel, Susanne
- Subjects
MEDICATION therapy management ,DRUG therapy ,DATA analysis ,PARASYMPATHOMIMETIC agents ,FRONTOTEMPORAL lobar degeneration ,MOTOR neuron diseases ,AMYOTROPHIC lateral sclerosis ,COMPARATIVE studies ,LONGITUDINAL method ,RESEARCH methodology ,MEDICAL cooperation ,RESEARCH ,EVALUATION research ,TREATMENT effectiveness ,NEUROPROTECTIVE agents ,CROSS-sectional method ,RILUZOLE - Published
- 2020
- Full Text
- View/download PDF
16. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
- Author
-
Ludolph, Albert C, Schuster, Joachim, Dorst, Johannes, Dupuis, Luc, Dreyhaupt, Jens, Weishaupt, Jochen H, Kassubek, Jan, Weiland, Ulrike, Petri, Susanne, Meyer, Thomas, Grosskreutz, Julian, Schrank, Berthold, Boentert, Matthias, Emmer, Alexander, Hermann, Andreas, Zeller, Daniel, Prudlo, Johannes, Winkler, Andrea S, Grehl, Torsten, and Heneka, Michael T
- Subjects
- *
MONOAMINE oxidase inhibitors , *RILUZOLE , *AMYOTROPHIC lateral sclerosis , *PARKINSON'S disease , *MOTOR neuron diseases , *PATIENTS , *HYDROCARBONS , *NEUROPROTECTIVE agents , *RESPIRATORY measurements , *STATISTICAL sampling , *BODY mass index , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *BLIND experiment , *DISEASE progression , *THERAPEUTICS - Abstract
Background: Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral sclerosis, both alone and in combination with riluzole. We sought to test whether or not rasagiline 1 mg/day can prolong survival in patients with amyotrophic lateral sclerosis also receiving riluzole.Methods: Patients with possible, probable, or definite amyotrophic lateral sclerosis were enrolled to our randomised, placebo-controlled, parallel-group, double-blind, phase 2 trial from 15 German network for motor neuron diseases (MND-NET) centres (university hospitals or clinics). Eligible patients were aged at least 18 years, had onset of progressive weakness within the 36 months before the study, had disease duration of more than 6 months and less than 3 years, and had a best-sitting slow vital capacity of at least 50%. After a 4-week screening period, eligible patients were randomly assigned (1:1) to receive either rasagiline (1 mg/day) or placebo in addition to riluzole (100 mg/day), after stratification for site of onset (bulbar or spinal) and study centre. Patients and all personnel assessing outcome parameters were masked to treatment allocation. Patients were followed up 2, 6, 12, and 18 months after randomisation. The primary endpoint was survival time, defined as the time to death or time to study cutoff date (ie, the last patient's last visit plus 14 days). Analyses of primary outcome and safety measures were done in all patients who received at least one dose of trial treatment (intention-to-treat population). The trial is registered with ClinicalTrials.gov, number NCT01879241.Findings: Between July 2, 2013, and Nov 11, 2014, 273 patients were screened for eligibility, and 252 patients were randomly assigned to receive rasagiline (n=127) or placebo (n=125). 126 patients taking rasagiline and 125 taking placebo were included in the intention-to-treat analysis. For the primary outcome, the survival probability at the end of the study was 0·43 (95% CI 0·25-0·59) in the rasagiline group (n=126) and 0·53 (0·43-0·62) in the placebo group (n=125). The estimated effect size (hazard ratio) was 0·91 (one-sided 97·5% CI -infinity to 1·34; p=0·31). Rasagiline was well tolerated, and most adverse events were due to amyotrophic lateral sclerosis disease progression rather than treatment; the most frequent of these were dysphagia (32 [25%] taking rasagiline vs 24 [19%] taking placebo) and respiratory failure (25 [20%] vs 31 [25%]). Frequency of adverse events were comparable between both groups.Interpretation: Rasagiline was safe in patients with amyotrophic lateral sclerosis. There was no difference between groups in the primary outcome of survival, although post-hoc analysis suggested that rasagiline might modify disease progression in patients with an initial slope of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised greater than 0·5 points per month at baseline. This should be confirmed in another clinical trial.Funding: Teva Pharmaceutical Industries. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
17. Phenotypic differences of amyotrophic lateral sclerosis (ALS) in China and Germany.
- Author
-
Rosenbohm, Angela, Liu, Mingsheng, Nagel, Gabriele, Peter, Raphael S., Cui, Bo, Li, Xiaoguang, Kassubek, Jan, Rothenbacher, Dietrich, Lulé, Dorothée, Cui, Liying, Ludolph, Albert C., and For the ALS Registry Swabia Study Group
- Subjects
AMYOTROPHIC lateral sclerosis treatment ,MOTOR neuron diseases ,GENOTYPE-environment interaction ,EPIDEMIOLOGY - Abstract
Objective: The aim of this study is to explore phenotypical differences of amyotrophic lateral sclerosis (ALS) between two cohorts from Germany and China.Methods: Registry-based studies of ALS were conducted in South-West Germany from 2010 to 2014 and an ALS clinic in Beijing from 2013 to 2016, respectively. Demographic and clinical features of 663 German and 276 Chinese ALS patients were collected and compared.Results: Mean age-at-onset was higher in German than in Chinese ALS patients [66.6 years (95% CI 65.7, 67.5) vs. 53.2 years (95% CI 52.0, 54.5)]. Age distribution of ALS patients peaked around 70-74 years in Germany and 50-54 years in China. Bulbar onset was more prevalent among German than among Chinese patients (35.9 vs. 22.8%). Diagnostic delay was higher in the Chinese than in the German study sample (12 vs. 5 months). Cognitive deficits were more pronounced in the Chinese cohort. Both cohorts differed in smoking habits, prevalence of diabetes and in body mass index (BMI).Conclusions: The apparent discrepancies between German and Chinese ALS patients (age at onset, gender distribution, bulbar forms, cognitive dysfunction, risk factors) reveal a quite different clinical phenotype in China, maybe due to socioeconomic status, environmental factors or genetic background. The observed differences in phenotype need to be pursued by further epidemiological studies on environmental and genetic risk factors. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Hypothalamic atrophy is related to body mass index and age at onset in amyotrophic lateral sclerosis.
- Author
-
Gorges, Martin, Vercruysse, Pauline, Müller, Hans-Peter, Huppertz, Hans-Jürgen, Rosenbohm, Angela, Nagel, Gabriele, Weydt, Patrick, Petersén, Åsa, Ludolph, Albert C., Kassubek, Jan, and Dupuis, Luc
- Subjects
ATROPHY ,AMYOTROPHIC lateral sclerosis ,BODY mass index ,HYPOTHALAMUS diseases ,MOTOR neuron diseases ,DIAGNOSIS ,AGE factors in disease ,BRAIN ,HYPOTHALAMUS ,LONGITUDINAL method ,MAGNETIC resonance imaging - Abstract
Objective: Our objective was to study the hypothalamic volume in a cohort of patients with amyotrophic lateral sclerosis (ALS) including symptomatic and presymptomatic ALS mutation carriers.Methods: High-resolution three-dimensional T1-weighted MRI datasets from 251 patients with sporadic ALS, 19 symptomatic and 32 presymptomatic ALS mutation carriers and 112 healthy controls (HC) were retrospectivally registered for manual delineation of the hypothalamus. The volume of the hypothalamus, in total or subdivided, was normalised to the intracranial volume and adjusted to age. Correlation analyses were performed with clinical and metabolic outcomes. Pathologically defined ALS stages were determined in vivo by diffusion tensor imaging (DTI).Results: We observed a severe atrophy of the hypothalamus both in patients with sporadic ALS (-21.8%, p<0.0001) and symptomatic ALS mutation carriers (-13.4%, p<0.001). The atrophy in patients with sporadic ALS was observed in both the anterior (-27.6% p<0.0001) and the posterior parts of the hypothalamus (-17.7%, p<0.0001). Notably, this atrophy was also observed in presymptomatic ALS mutation carriers (-15.5%, p<0.001) and was unrelated to whole brain volume atrophy or disease stage as assessed using DTI or functional status. Hypothalamic volume was correlated with body mass index (BMI) in patients with sporadic ALS (p=0.0434, ρ=+0.1579), and this correlation was much stronger in patients with familial ALS (fALS) (p=0.0060, ρ=+0.6053). Anterior hypothalamic volume was correlated with age at onset, but not with survival after MRI.Conclusions: Hypothalamus is atrophied in ALS, even in premorbid stages, and correlates with BMI, especially in fALS. Decreased anterior hypothalamic volume is associated with earlier onset of disease. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
19. Perception of Emotional Facial Expressions in Amyotrophic Lateral Sclerosis (ALS) at Behavioural and Brain Metabolic Level.
- Author
-
Aho-Özhan, Helena E. A., Keller, Jürgen, Heimrath, Johanna, Uttner, Ingo, Kassubek, Jan, Birbaumer, Niels, Ludolph, Albert C., and Lulé, Dorothée
- Subjects
AMYOTROPHIC lateral sclerosis ,FACIAL expression ,EMOTIONS ,GENDER differences (Psychology) ,FUNCTIONAL magnetic resonance imaging - Abstract
Introduction: Amyotrophic lateral sclerosis (ALS) primarily impairs motor abilities but also affects cognition and emotional processing. We hypothesise that subjective ratings of emotional stimuli depicting social interactions and facial expressions is changed in ALS. It was found that recognition of negative emotions and ability to mentalize other’s intentions is reduced. Methods: Processing of emotions in faces was investigated. A behavioural test of Ekman faces expressing six basic emotions was presented to 30 ALS patients and 29 age-, gender and education matched healthy controls. Additionally, a subgroup of 15 ALS patients that were able to lie supine in the scanner and 14 matched healthy controls viewed the Ekman faces during functional magnetic resonance imaging (fMRI). Affective state and a number of daily social contacts were measured. Results: ALS patients recognized disgust and fear less accurately than healthy controls. In fMRI, reduced brain activity was seen in areas involved in processing of negative emotions replicating our previous results. During processing of sad faces, increased brain activity was seen in areas associated with social emotions in right inferior frontal gyrus and reduced activity in hippocampus bilaterally. No differences in brain activity were seen for any of the other emotional expressions. Inferior frontal gyrus activity for sad faces was associated with increased amount of social contacts of ALS patients. Conclusion: ALS patients showed decreased brain and behavioural responses in processing of disgust and fear and an altered brain response pattern for sadness. The negative consequences of neurodegenerative processes in the course of ALS might be counteracted by positive emotional activity and positive social interactions. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis.
- Author
-
Müller, Hans-Peter, Turner, Martin R., Grosskreutz, Julian, Abrahams, Sharon, Bede, Peter, Govind, Varan, Prudlo, Johannes, Ludolph, Albert C., Filippi, Massimo, Kassubek, Jan, and Neuroimaging Society in ALS (NiSALS) DTI Study Group
- Subjects
AMYOTROPHIC lateral sclerosis ,DIFFUSION tensor imaging ,BIOMARKERS ,ANISOTROPY ,MOTOR neuron diseases ,ALGORITHMS ,BRAIN ,COMPARATIVE studies ,DIAGNOSTIC imaging ,LONGITUDINAL method ,MAGNETIC resonance imaging ,RESEARCH methodology ,MEDICAL cooperation ,COMPUTERS in medicine ,NERVOUS system ,PROGNOSIS ,RESEARCH ,RESEARCH funding ,EVALUATION research ,RETROSPECTIVE studies - Abstract
Objective: Damage to the cerebral tissue structural connectivity associated with amyotrophic lateral sclerosis (ALS), which extends beyond the motor pathways, can be visualised by diffusion tensor imaging (DTI). The effective translation of DTI metrics as biomarker requires its application across multiple MRI scanners and patient cohorts. A multicentre study was undertaken to assess structural connectivity in ALS within a large sample size.Methods: 442 DTI data sets from patients with ALS (N=253) and controls (N=189) were collected for this retrospective study, from eight international ALS-specialist clinic sites. Equipment and DTI protocols varied across the centres. Fractional anisotropy (FA) maps of the control participants were used to establish correction matrices to pool data, and correction algorithms were applied to the FA maps of the control and ALS patient groups.Results: Analysis of data pooled from all centres, using whole-brain-based statistical analysis of FA maps, confirmed the most significant alterations in the corticospinal tracts, and captured additional significant white matter tract changes in the frontal lobe, brainstem and hippocampal regions of the ALS group that coincided with postmortem neuropathological stages. Stratification of the ALS group for disease severity (ALS functional rating scale) confirmed these findings.Interpretation: This large-scale study overcomes the challenges associated with processing and analysis of multiplatform, multicentre DTI data, and effectively demonstrates the anatomical fingerprint patterns of changes in a DTI metric that reflect distinct ALS disease stages. This success paves the way for the use of DTI-based metrics as read-out in natural history, prognostic stratification and multisite disease-modifying studies in ALS. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
21. Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss.
- Author
-
Scekic‐Zahirovic, Jelena, Sendscheid, Oliver, El Oussini, Hajer, Jambeau, Mélanie, Sun, Ying, Mersmann, Sina, Wagner, Marina, Dieterlé, Stéphane, Sinniger, Jérome, Dirrig‐Grosch, Sylvie, Drenner, Kevin, Birling, Marie‐Christine, Qiu, Jinsong, Zhou, Yu, Li, Hairi, Fu, Xiang‐Dong, Rouaux, Caroline, Shelkovnikova, Tatyana, Witting, Anke, and Ludolph, Albert C
- Subjects
MUTANT proteins ,FRONTOTEMPORAL dementia ,AMYOTROPHIC lateral sclerosis ,RNA-binding proteins ,MOTOR neuron diseases ,CYTOPLASM - Abstract
FUS is an RNA-binding protein involved in amyotrophic lateral sclerosis ( ALS) and frontotemporal dementia ( FTD). Cytoplasmic FUS-containing aggregates are often associated with concomitant loss of nuclear FUS. Whether loss of nuclear FUS function, gain of a cytoplasmic function, or a combination of both lead to neurodegeneration remains elusive. To address this question, we generated knockin mice expressing mislocalized cytoplasmic FUS and complete FUS knockout mice. Both mouse models display similar perinatal lethality with respiratory insufficiency, reduced body weight and length, and largely similar alterations in gene expression and mRNA splicing patterns, indicating that mislocalized FUS results in loss of its normal function. However, FUS knockin mice, but not FUS knockout mice, display reduced motor neuron numbers at birth, associated with enhanced motor neuron apoptosis, which can be rescued by cell-specific CRE-mediated expression of wild-type FUS within motor neurons. Together, our findings indicate that cytoplasmic FUS mislocalization not only leads to nuclear loss of function, but also triggers motor neuron death through a toxic gain of function within motor neurons. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients.
- Author
-
Steinacker, Petra, Feneberg, Emily, Weishaupt, Jochen, Brettschneider, Johannes, Tumani, Hayrettin, Andersen, Peter M., von Arnim, Christine A. F., Böhm, Sarah, Kassubek, Jan, Kubisch, Christian, Lulé, Dorothée, Müller, Hans-Peter, Muche, Rainer, Pinkhardt, Elmar, Oeckl, Patrick, Rosenbohm, Angela, Anderl-Straub, Sarah, Volk, Alexander E., Weydt, Patrick, and Ludolph, Albert C.
- Subjects
MOTOR neuron diseases ,CYTOPLASMIC filaments ,BIOMARKERS ,CEREBROSPINAL fluid ,DISEASE progression ,DIFFERENTIAL diagnosis ,DIAGNOSIS ,AMYOTROPHIC lateral sclerosis ,CYTOPLASM ,DNA ,LONGITUDINAL method ,NERVE tissue proteins ,NEUROLOGIC examination ,PROGNOSIS ,RESEARCH evaluation ,PREDICTIVE tests - Abstract
Objectives: Biomarkers for the diagnosis of motoneuron diseases (MND) are urgently needed to improve the diagnostic pathway, patient stratification and monitoring. The aim of this study was to validate candidate markers for MND in cerebrospinal fluid (CSF) and specify cut-offs based on large patient cohorts by especially considering patients who were seen under the initial differential diagnosis (MND mimics).Methods: In a prospective study, we investigated CSF of 455 patients for neurofilament light chain (NfL), phosphorylated heavy chain (pNfH), tau protein (Tau) and phospho-tau protein (pTau). Analysed cohorts included patients with apparently sporadic and familial amyotrophic lateral sclerosis (ALS) and primary lateral sclerosis (PLS) (MND, n=253), MND mimics (n=85) and neurological control groups. Cut-off values were specified, and diagnostic performance and correlation with progression were analysed.Results: Nfs were significantly higher in the MND group compared to the control groups, whereas Tau and pTau did not differ. At a cut-off level of 2200 pg/mL for NfL, a 77% diagnostic sensitivity (CI 71% to 82%), 85% specificity (CI 79% to 90%) and 87% positive predictive value (PPV) (CI 81% to 91%) were achieved. For pNfH, we calculated 83% sensitivity (CI 78% to 88%), 77% specificity (CI 71% to 83%) and 82% PPV (CI 77% to 86%) at 560 pg/mL. There were no significant differences between sporadic and genetic ALS or PLS. Nf levels were elevated at early disease stage, and correlated moderately with MND progression and duration.Conclusions: Neurofilaments in CSF have a high relevance for the differential diagnosis of MNDs and should be included in the diagnostic work-up of patients. Their value as prognostic markers should be investigated further. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
23. The diagnostic value of midbrain hyperechogenicity in ALS is limited for discriminating key ALS differential diagnoses.
- Author
-
Hermann, Andreas, Reuner, Ulrike, Schaefer, Jochen, Fathinia, Panteha, Leimert, Tordis, Kassubek, Jan, Leimert, Mario, Ludolph, Albert C., and Storch, Alexander
- Subjects
AMYOTROPHIC lateral sclerosis ,MESENCEPHALON ,MOTOR neuron diseases ,SUBSTANTIA nigra ,MYASTHENIA gravis ,ULTRASONIC imaging - Abstract
Background: Hyperechogenicity of the substantia nigra was recently reported in patients with sporadic ALS with a frequency similar to PD. Data on the diagnostic utility compared to key differential diagnoses of ALS do not exist yet. Methods: We prospectively enrolled 43 patients with ALS, 29 with myasthenia gravis, 25 patients with inflammatory neuropathy, and 13 with cervical canal stenosis. All patients were examined by a blinded investigator using transcranial B-mode sonography planimetrically measuring hyperechogenic areas of the midbrain representing the substantia nigra. Results: Mean midbrain hyperechogenic area was increased in ALS compared to non-ALS differentials. ROC analysis revealed only small area under the curve for detecting ALS (AUC: 0.669 [95%CI: 0.56-0.78]; p = 0.006). Highest Youden index was observed for area size of <0.14 cm² (Youden index: 0.28). Using this cut-off score and that generated from normative data of healthy controls, area size measurements provided a sensitivity of only 46-58% and specificity of 69-83% for detecting ALS. No correlations of hyperechogenic area sizes in ALS patients were found to age, gender, ALS subtype (bulbar versus spinal form), disease duration or ALS-FRS-R score. Conclusions: Midbrain hyperechogenicity is reproducibly found in ALS patients, but its diagnostic value for discriminating ALS from its key differentials is limited. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
24. Ex post facto assessment of diffusion tensor imaging metrics from different MRI protocols: Preparing for multicentre studies in ALS.
- Author
-
Rosskopf, Johannes, Müller, Hans-Peter, Dreyhaupt, Jens, Gorges, Martin, Ludolph, Albert C., and Kassubek, Jan
- Subjects
DIFFUSION tensor imaging ,MAGNETIC resonance imaging ,AMYOTROPHIC lateral sclerosis ,MOTOR neuron diseases - Abstract
Diffusion tensor imaging (DTI) for assessing ALS-associated white matter alterations has still not reached the level of a neuroimaging biomarker. Since large-scale multicentre DTI studies in ALS may be hampered by differences in scanning protocols, an approach for pooling of DTI data acquired with different protocols was investigated. Three hundred and nine datasets from 170 ALS patients and 139 controls were collected ex post facto from a monocentric database reflecting different scanning protocols. A 3D correction algorithm was introduced for a combined analysis of DTI metrics despite different acquisition protocols, with the focus on the CST as the tract correlate of ALS neuropathological stage 1. A homogenous set of data was obtained by application of 3D correction matrices. Results showed that a fractional anisotropy (FA) threshold of 0.41 could be defined to discriminate ALS patients from controls (sensitivity/specificity, 74%/72%). For the remaining test sample, sensitivity/specificity values of 68%/74% were obtained. In conclusion, the objective was to merge data recorded with different DTI protocols with 3D correction matrices for analyses at group level. These post processing tools might facilitate analysis of large study samples in a multicentre setting for DTI analysis at group level to aid in establishing DTI as a non-invasive biomarker for ALS. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
25. Adipose Tissue Distribution Predicts Survival in Amyotrophic Lateral Sclerosis.
- Author
-
Lindauer, Eva, Dupuis, Luc, Müller, Hans-Peter, Neumann, Heiko, Ludolph, Albert C., and Kassubek, Jan
- Subjects
ADIPOSE tissues ,AMYOTROPHIC lateral sclerosis ,CAUSES of death ,WEIGHT loss ,NEURODEGENERATION ,MOTOR neuron diseases ,ENERGY metabolism ,DIAGNOSIS - Abstract
Background: amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that leads to death within a few years after diagnosis. Malnutrition and weight loss are frequent and are indexes of poor prognosis. Total body fat and fat distribution have not been studied in ALS patients. Objectives: Our aim was to describe adipose tissue content and distribution in ALS patients. Design: We performed a cross-sectional study in a group of ALS patients (n = 62, mean disease duration 22 months) along with age and gender matched healthy controls (n = 62) using a MRI-based method to study quantitatively the fat distribution. Results: Total body fat of ALS patients was not changed as compared with controls. However, ALS patients displayed increased visceral fat and an increased ratio of visceral to subcutaneous fat. Visceral fat was not correlated with clinical severity as judged using the ALS functional rating scale (ALS-FRS-R), while subcutaneous fat in ALS patients correlated positively with ALS-FRS-R and disease progression. Multiple regression analysis showed that gender and ALS-FRS-R, but not site of onset, were significant predictors of total and subcutaneous fat. Increased subcutaneous fat predicted survival in male patients but not in female patients (p<0.05). Conclusions: Fat distribution is altered in ALS patients, with increased visceral fat as compared with healthy controls. Subcutaneous fat content is a predictor of survival of ALS patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
26. Diffusion Tensor Magnetic Resonance Imaging of the Brain in APP Transgenic Mice: A Cohort Study.
- Author
-
Müller, Hans-Peter, Kassubek, Jan, Vernikouskaya, Ina, Ludolph, Albert C., Stiller, Detlef, and Rasche, Volker
- Subjects
BRAIN imaging ,MAGNETIC resonance imaging ,DIFFUSION tensor imaging ,TRANSGENIC mice ,COHORT analysis ,MOTOR neurons - Abstract
Introduction: Fast in-vivo high resolution diffusion tensor imaging (DTI) of the mouse brain has recently been shown to enable cohort studies by the combination of appropriate pulse sequences and cryogenically cooled resonators (CCR). The objective of this study was to apply this DTI approach at the group level to β-amyloid precursor protein (APP) transgenic mice. Methods: Twelve mice (5 wild type, 7 APP transgenic tg2576) underwent DTI examination at 156
2 ×250 µm3 spatial resolution with a CCR at ultrahigh field (11.7 T). Diffusion images were acquired along 30 gradient directions plus 5 references without diffusion encoding with a total acquisition time of 35 minutes. Fractional anisotropy (FA) maps were statistically compared by whole brain-based spatial statistics (WBSS) at the group level vs. wild type controls. Results: FA-map comparison showed characteristic regional patterns of differences between the groups with localizations associated with Alzheimer’s disease in humans, such as the hippocampus, the entorhinal cortex, and the caudoputamen. Conclusion: In this proof-of-principle study, regions associated with amyloid-β deposition could be identified by WBSS of FA maps in APP transgenic mice vs. wild type mice. Thus, DTI in the mouse brain acquired at 11.7 T by use of a CCR was demonstrated to be feasible for cohort studies. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
27. Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) - registry Swabia.
- Author
-
Nagel, Gabriele, Ünal, Hatice, Rosenbohm, Angela, Ludolph, Albert C., and Rothenbacher, Dietrich
- Subjects
AMYOTROPHIC lateral sclerosis ,REPORTING of diseases ,RESEARCH protocols ,MOTOR neuron diseases ,CASE-control method ,PATHOLOGICAL physiology - Abstract
Background: The social and medical impact of rare diseases is increasingly recognized. Amyotrophic lateral sclerosis (ALS) is the most prevalent of the motor neuron diseases. It is characterized by rapidly progressive damage to the motor neurons with a survival of 2-5 years for the majority of patients. The objective of this work is to describe the study protocol and the implementation steps of the amyotrophic lateral sclerosis (ALS) registry Swabia, located in the South of Germany. Methods/Design: The ALS registry Swabia started in October 2010 with both, the retrospective (01.10.2008- 30.09.2010) and prospective (from 01.10.2010) collection of ALS cases, in a target population of 8.6 million persons in Southern Germany. In addition, a population based case-control study was implemented based on the registry that also included the collection of various biological materials. Retrospectively, 420 patients (222 men and 198 women) were identified. Prospectively data of ALS patients were collected, of which about 70% agreed to participate in the population-based case-control study. All participants in the case-control study provided also a blood sample. The prospective part of the study is ongoing. Discussion: The ALS registry Swabia has been implemented successfully. In rare diseases such as ALS, the collaboration of registries, the comparison with external samples and biorepositories will facilitate to identify risk factors and to further explore the potential underlying pathophysiological mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
28. Neuroanatomical patterns of cerebral white matter involvement in different motor neuron diseases as studied by diffusion tensor imaging analysis.
- Author
-
Müller, Hans-Peter, Unrath, Alexander, Huppertz, Hans-Jürgen, Ludolph, Albert C., and Kassubek, Jan
- Subjects
MOTOR neuron diseases ,DIFFUSION tensor imaging ,AMYOTROPHIC lateral sclerosis ,PARAPARESIS ,MAGNETIC resonance imaging - Abstract
This study was designed to investigate differences of white matter (WM) involvement patterns in various motor neuron disorders (MND) by use of diffusion tensor imaging (DTI).DTI was acquired in ALS ( n == 20), primary lateral sclerosis ( n == 20), pure hereditary spastic paraparesis (HSP) ( n == 20), and complicated HSP ( n == 12). The data analysis was performed by voxelwise comparison of fractional anisotropy (FA) maps at group level together with fibre tracking in regions of interest (ROI) accompanied by tractwise fractional anisotropy statistics. DTI analysis revealed widespread patterns of alterations with a predominant deterioration of the motor system. These alterations encompassed, as the key structures, not only the corticospinal tracts (CST) but also distinct areas of the corpus callosum (CC), in particular its motor segment III. In conclusion, whole brain-based and tract-based DTI analysis was able to define a distinct WM pathoanatomy of different MND. These results may serve as an additional guidance in the identification of MRI-based parameters by showing a consistent CST and CC involvement, with differences in the extent of pathology, across a range of clinically different disorders. For potential future developments in MRI diagnostics in MND, a (perhaps multiparametric) ROI-based approach should include CST and the CC motor segment. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
29. Neuroimaging of motor neuron diseases.
- Author
-
Kassubek, Jan, Ludolph, Albert C., and Müller, Hans-Peter
- Abstract
It is agreed that conventional magnetic resonance imaging (MRI) of the brain and spine is one of the core elements in the differential diagnostic work up of patients with clinical signs of motor neuron diseases (MNDs), for example amyotrophic lateral sclerosis (ALS), to exclude MND mimics. However, the sensitivity and specificity of MRI signs in these disorders are moderate to low and do not have an evidence level higher than class IV (good clinical practice point). Currently computerized MRI analyses in ALS and other MNDs are not techniques used for individual diagnosis. However, they have improved the anatomical understanding of pathomorphological alterations in gray and white matter in various MNDs and the changes in functional networks by quantitative comparisons between patients with MND and controls at group level. For multiparametric MRI protocols, including T1-weighted three-dimensional datasets, diffusion-weighted imaging and functional MRI, the potential as a ‘dry’ surrogate marker is a subject of investigation in natural history studies with well defined patients. The additional value of MRI with respect to early diagnosis at an individual level and for future disease-modifying multicentre trials remains to be defined. There is still the need for more longitudinal studies in the very early stages of disease or when there is clinical uncertainty and for better standardization in the acquisition and postprocessing of computer-based MRI data. These requirements are to be addressed by establishing quality-controlled multicentre neuroimaging databases. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
30. Signs of impaired selective attention in patients with amyotrophic lateral sclerosis.
- Author
-
Pinkhardt, Elmar H., Jürgens, Reinhart, Becker, Wolfgang, Mölle, Matthias, Born, Jan, Ludolph, Albert C., and Schreiber, Herbert
- Subjects
AMYOTROPHIC lateral sclerosis ,NEUROMUSCULAR diseases ,HUNTINGTON disease ,NEUROPSYCHOLOGICAL tests ,MOTOR neuron diseases - Abstract
The evidence for involvement of extramotor cortical areas in non-demented patients with amyotrophic lateral sclerosis (ALS) has been provided by recent neuropsychological and functional brain imaging studies. The aim of this study was to investigate possible alterations in selective attention, as an important constituent part of frontal brain function in ALS patients. A classical dichotic listening task paradigm was employed to assess event-related EEG potential (ERPs) indicators of selective attention as well as preattentive processing of mismatch, without interference by motor impairment. A total of 20 patients with sporadic ALS according to the revised El Escorial criteria and 20 healthy controls were studied. Additionally a neuropsychological test battery of frontotemporal functions was applied. Compared with the controls, the ALS patients showed a distinct decrease of the fronto-precentral negative difference wave (Nd), i.e., the main ERP indicator of selective attention. Analysis of the P3 component of the ERPs indicated an increased processing of non-relevant stimuli in ALS patients confirming a reduced focus of attention. We conclude impaired selective attention reflects a subtle variant of frontotemporal dementia frequently observed in ALS patients at a relatively early stage of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
31. Vacuolization correlates with spin–spin relaxation time in motor brainstem nuclei and behavioural tests in the transgenic G93A-SOD1 mouse model of ALS.
- Author
-
Bucher, Selina, Braunstein, Kerstin E., Niessen, Heiko G., Kaulisch, Thomas, Neumaier, Michael, Boeckers, Tobias M., Stiller, Detlef, and Ludolph, Albert C.
- Subjects
MAGNETIC resonance imaging ,TRANSGENIC mice ,AMYOTROPHIC lateral sclerosis ,MOTOR neuron diseases ,DIAGNOSIS ,SUPEROXIDE dismutase ,MANGANESE enzymes - Abstract
In recent years, magnetic resonance imaging (MRI) has emerged as a preferred tool for the diagnosis of amyotrophic lateral sclerosis (ALS) in humans. A widely used animal model for human ALS is the G93A-superoxide dismutase 1 (G93A-SOD1) transgenic mouse model. However, the mechanisms for the selective degeneration of motor neurons in the brainstem and spinal cord are still uncertain. In our study, we applied MRI at 4.7 Tesla to non-invasively evaluate pathological alterations in the brainstem of this animal model and to follow the progression of the disease. Extending previous investigation, we used the relaxation parameter T
2 as a suitable measure for the progression of ALS, and evaluated the potential agreement with histological evaluation and behavioural data of open-field tests. In the brainstem of G93A-SOD1 mice, T2 values were significantly increased in the motor nuclei Nc. V, Nc. VII and Nc. XII, as early as Day 80, i.e. before the average disease onset at about Day 90. Moreover, this increase is associated with a progressive development of vacuoles in the brainstem motor nuclei and a significantly decreased performance in behavioural tests. Overall, MRI is a very sensitive tool to obtain correlates for neuronal degeneration in vivo. Furthermore, MRI enables us to investigate a follow up at different time points of the disease. These advantages are especially useful for therapeutic studies with respect to survival rates of motor neurons using mouse models. Finally, our data suggest that MRI does not only resemble the findings of behavioural tests, but is potentially superior to behavioural studies. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
32. Brain metabolites in definite amyotrophic lateral sclerosis.
- Author
-
Unrath, Alexander, Ludolph, Albert C., and Kassubek, Jan
- Subjects
- *
AMYOTROPHIC lateral sclerosis , *BIOMARKERS , *MAGNETIC resonance , *MOTOR neuron diseases , *SPECTRUM analysis , *MOTOR cortex - Abstract
Biomarkers beyond clinical assessment are needed in patients who suffer from amyotrophic lateral sclerosis (ALS). Here, single-voxel proton magnetic resonance spectroscopy (1H MRS) of the gray matter of the motor cortex and the white matter including the pyramidal tracts was used to investigate concentrations of N-acetylaspartate (NAA), creatine (Cr), choline (Cho), myoinositol, glutamate, and glutamine in patients with definite ALS in a longitudinal design (three measurements at study inclusion, after 3 and 6 months). A volume-corrected analysis of gray and white matter fractions within the volumes of interest (VOI) was performed for the identification of the absolute metabolite concentrations. The patient group showed a significant decline of the compound NAA over time in the motor cortex areas both of the clinically more and less affected hemisphere between first measurement and month 6 and for the less affected side additionally between first measurement and month 3. For the NAA/(Cr + Cho) ratio, significant decline in the less affected hemisphere was observed from the first measurement to month 3 and to month 6 as well as from month 3 to month 6. In contrast, neither NAA nor the NAA/(Cr + Cho) ratios in the white matter areas showed any significant alterations. All other compounds showed no significant changes over time. In summary, the longitudinal changes of cortical metabolite concentrations in the course of ALS could be assessed by optimized 1H MRS techniques at group level, so that 1H MRS parameters, in particular volume-corrected values of NAA in the clinically less affected hemisphere, seem to have the potential to serve as a surrogate marker for monitoring ALS disease progression. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
33. Brain responses to emotional stimuli in patients with amyotrophic lateral sclerosis (ALS).
- Author
-
Lulé, Dorothée, Diekmann, Volker, Anders, Silke, Kassubek, Jan, Kübler, Andrea, Ludolph, Albert C., and Birbaumer, Niels
- Subjects
AMYOTROPHIC lateral sclerosis ,EMOTIONS ,BRAIN ,MOTOR neuron diseases ,SOCIAL interaction ,FACIAL expression ,MEDICAL research - Abstract
Amyotrophic lateral sclerosis (ALS), a progressive motor neuron disease, affects movement and communication abilities and emotional processing. Subjective ratings of emotional stimuli depicting social interactions and facial expressions differed significantly between ALS patients and healthy controls in a previous study with a reduction of negative emotional valence (pleasantness) and lower subjective arousal (excitement) in ALS patients. In the present study, sixty similar emotional slides were presented to 13 ALS patients, 15 matched healthy controls and six tetraplegic patients. Subjective reports of valence and arousal as well as brain responses to the affective pictures using functional magnetic resonance imaging (fMRI) were measured. The picture series was presented twice with a 6-months interval to investigate effects of disease progression. ALS patients presented an increased brain response in the right supramarginal area and a reduced brain response in extrastriate visual areas at both measurements compared with healthy controls. Within the ALS patients' group a reduction of brain responses in the anterior insula at the follow-up was correlated with the subjective arousal. The reduced response in the anterior insula is tentatively interpreted as indicating reduced arousal during the course of the disease at the neural and behavioural level. The reduction of activity in extrastriate visual areas might be similarly interpreted. The increased brain response in the right supramarginal area of ALS patients might represent an altered sensitivity to social-emotional cues. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
34. Metabolic progression markers of neurodegeneration in the transgenic G93A-SOD1 mouse model of amyotrophic lateral sclerosis.
- Author
-
Niessen, Heiko G., Debska‐Vielhaber, Grazyna, Sander, Kerstin, Angenstein, Frank, Ludolph, Albert C., Hilfert, Liane, Willker, Wieland, Leibfritz, Dieter, Heinze, Hans‐Jochen, Kunz, Wolfram S., and Vielhaber, Stefan
- Subjects
AMYOTROPHIC lateral sclerosis ,NEURODEGENERATION ,AMINO acids ,PROTON magnetic resonance spectroscopy ,MOTOR neuron diseases ,TRANSGENIC mice - Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a progressive loss of motor neurons. Visualizing corresponding metabolic changes in the brain of patients with ALS with proton magnetic resonance spectroscopy (
1 H-MRS) may provide surrogate markers for an early disease detection, for monitoring the progression and for evaluating a treatment response. The primary objective of our study was to evaluate whether modifications in MR metabolite levels occur before clinical disease onset, and whether these changes are directly linked to a distinct spatial progression pattern in the CNS. Therefore, age-dependent alterations in the cerebral and spinal metabolic profile in the mouse model of ALS overexpressing the mutated human G93A-superoxide dismutase 1 (G93A-SOD1) were determined by high-resolution MRS of tissue extracts at 14.1 Tesla. Both non-transgenic mice (control mice) and transgenic mice overexpressing the non-mutated human SOD1 (tg-SOD1) served as controls. In the spinal cord of G93A-SOD1 mice significantly decreased levels of N-acetyl aspartate were already detected 34 days postpartum, i.e. about 60 days before the average disease onset caused by motor neuron decline. In addition, glutamine and γ-aminobutyric acid concentrations were significantly diminished at Day 75, which is still in the presymptomatic phase of the disease. These metabolic changes were further progressive in the course of the disease and started to involve the brainstem at Day 75. Overall, high-resolution1 H-MRS allows a sensitive spatial and temporal metabolite profiling in the presymptomatic phase of ALS even before significant neuronal cell loss occurs. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
35. Motor protein diseases of the nervous system.
- Author
-
Hanemann, C. Oliver and Ludolph, Albert C.
- Subjects
- *
MOTOR neuron diseases , *ENERGY metabolism , *NERVOUS system , *MOTOR neurons , *AXONAL transport , *PATIENTS - Abstract
Motor proteins link concepts of impaired axonal transport with concepts of impaired energy metabolism in motor neuron disease. Thus it is not surprising that in recent years several reports on the relevance of motor protein function in mice models for motor neuron disease as well as motor neuron patients have appeared. This article summarizes the broad spectrum of neurological phenotypes, which are caused by alterations of motor protein function. This is likely to add to the understanding of motor neuron disease and may be relevant in terms of future therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
36. Emotional responding in amyotrophic lateral sclerosis.
- Author
-
Lulé, Dorothée, Kurt, Anja, Jürgens, Reinhart, Kassubek, Jan, Diekmann, Volker, Kraft, Eduard, Neumann, Nicola, Ludolph, Albert C., Birbaumer, Niels, and Anders, Silke
- Subjects
AMYOTROPHIC lateral sclerosis ,MOTOR neuron diseases ,NEUROMUSCULAR diseases ,EMOTIONS ,PSYCHOPHYSIOLOGY ,NEUROLOGY - Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal disease, leaving the patient in a partially or completely deafferented state. In an explorative study, we investigated responses to visual socio–emotional stimuli in ALS patients. Pictures from the International Affective Picture System (IAPS) were verbally judged by 12 moderately affected ALS patients with a spinal onset and a slow progression and 18 age–matched controls, and data were compared with psychophysiological responses. Verbal emotional judgments of patients were more positive than ratings of controls. Regarding arousal, patients neutralized extreme pictures, in that they rated calm pictures as more exciting than controls and exciting pictures as more calm. These changes of emotional processing were unrelated to depression or frontal lobe dysfunction. There were no major differences between patients and controls concerning physiological responses to emotional stimuli. We conclude that emotional responses of ALS patients tend to be altered towards positive valence and towards a more balanced arousal state in early stages of the disease. These findings contradict assumptions of a generally negative impact of the disease on the emotional disposition and may indicate compensatory cognitive or neuroplastic changes. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
37. Mechanisms of Disease: Motoneuron Disease Aggravated by Transgenic Expression of a Functionally Modified AMPA Receptor Subunit.
- Author
-
KUNER, ROHINI, GROOM, ANTHONY J., MÜLLER, GERALD, KORNAU, HANS‐CHRISTIAN, STEFOVSKA, VANYA, BRESINK, IRIS, HARTMANN, BETTINA, TSCHAUNER, KARSTEN, WAIBEL, STEFAN, LUDOLPH, ALBERT C., IKONOMIDOU, CHRYSANTHY, SEEBURG, PETER H., and TURSKI, LECHOSLAW
- Subjects
MEDICAL research ,MOTOR neuron diseases ,NEUROMUSCULAR diseases ,NEURODEGENERATION ,GENETIC mutation - Abstract
To reveal whether increased Ca
2+ permeability of glutamate AMPA channels triggered by the transgene for G1uR-B(N) induces decline in motor functions and neurodegeneration in the spinal cord, we evaluated growth, motor coordination, and spinal reflexes in transgenic G1uR-B(N) and wild-type (wt) mice. To reveal whether the transgenic G1uR-B(N) expression aggravates the course of motoneuron disease in SOU1 mice, we mated heterozygous G1uR-B(N) and SOU1 [C57BL6Ic0-TgN(hSOD1-G93A)lGur] mice to generate double-transgenic progeny. The phenotypic sequelae in mice carrying mutations were evaluated by monitoring growth, motor coordination, and survival. Neuronal degeneration was assessed by morphological and stereological analysis of spinal cord and brain. We found that transgenic expression in mice of G1uR-B(N)-containing glutamate AMPA receptors with increased Ca2! permeability leads to a late-onset degeneration of neurons in the spinal cord and decline of motor functions. Neuronal death progressed over the entire life span, but manifested clinically in late adulthood, resembling the course of a slow neurodegenerative disorder. Additional transgenic expression of mutated human SODl accelerated disease progression, aggravated severity of motor decline, and decreased survival. These observations reveal that moderate, but persis- tently elevated Ca2+ influx via glutamate AMPA channels causes degeneration of spinal motoneurons and motor decline over the span of life. These features resemble the course of sporadic amyotrophic lateral sclerosis (ALS) in humans and suggest that modified function of glutamate AMPA channels may be causally linked to pathogenesis of ALS. [ABSTRACT FROM AUTHOR]- Published
- 2005
- Full Text
- View/download PDF
38. MR-Pathologic Comparison of the Upper Spinal Cord in Different Motor Neuron Diseases.
- Author
-
Sperfeld, Anne-Dorte, Bretschneider, Volker, Flaith, Leonie, Unrath, Alexander, Hanemann, C. Oliver, Ludolph, Albert C., and Kassubek, Jan
- Subjects
MOTOR neuron diseases ,SPINAL cord ,MAGNETIC resonance imaging ,BRAIN ,CENTRAL nervous system ,NEUROMUSCULAR diseases - Abstract
This MRI study was performed to evaluate in vivo alterations of the spinal cord in defined subgroups of motor neuron diseases. Standard MRI examinations of the cervical and thoracic spinal cord in sporadic amyotrophic lateral sclerosis (ALS; n = 39), sporadic lower motor neuron disease (LMND; n = 19), Kennedy’s disease (KD; n = 19) and a control group (n = 96) were analyzed with respect to spinal cord signal changes and the thickness of the spinal cord. No significant changes in thickness or signal alterations were observed when comparing ALS, LMND and control groups with one another. However, in KD patients significant upper spinal cord atrophy was detected at the cervical level as compared with all other groups. At the thoracic level, KD patients had significant upper cord atrophy as compared with controls and LMND. Marked atrophy of the upper spinal cord seems to be a feature of the KD-associated central-peripheral distal axonopathy. Copyright © 2005 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
39. Hereditary motor neuropathies and motor neuron diseases: which is which.
- Author
-
Hanemann, Clemens O. and Ludolph, Albert C.
- Subjects
- *
MOTOR neuron diseases , *AMYOTROPHIC lateral sclerosis - Abstract
When Charcot first defined amyotrophic lateral sclerosis (ALS) he used the clinical and neuropathological pattern of vulnerability as a guideline. Similarly other motor neuron diseases such as the spinal muscular atrophies (SMA) and the motor neuropathies (MN) were grouped following clinical criteria. However, ever since the etiology of these diseases has started to be disclosed by genetics, we have learnt that the limits of the syndromes are not as well defined as our forefathers thought. A mutation leading to ALS can also be associated with the clinical picture of spinal muscular atrophy; even more unexpected is the overlap of the so-called motor neuropathies with the clinical syndrome of slowly progressive ALS or that primary lateral sclerosis (PLS) can be caused by the same gene as that responsible for some cases of ALS. In this review we summarise recent work showing that there is a considerable overlap between CMT, MN, SMA, ALS and PLS. Insights into these phenotypes should lead to study of the variants of motor neuron disease and possibly to a reclassification. This comprehensive review should help to improve understanding of the pathogenesis of motor neuron degeneration and finally may aid the research for urgently needed new treatment strategies, perhaps with validity for the entire group of motor neuron diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
40. Cognitive Performance of Patients with Adult 5q-Spinal Muscular Atrophy and with Amyotrophic Lateral Sclerosis.
- Author
-
Osmanovic, Alma, Wieselmann, Gary, Mix, Lucas, Siegler, Hannah Alexandra, Kumpe, Mareike, Ranxha, Gresa, Wurster, Claudia D., Steinke, Alexander, Ludolph, Albert C., Kopp, Bruno, Lulé, Dorothée, Petri, Susanne, and Schreiber-Katz, Olivia
- Subjects
AMYOTROPHIC lateral sclerosis ,MUSCULAR atrophy ,MOTOR neuron diseases ,SPINAL muscular atrophy ,VOCABULARY tests - Abstract
Motor neuron diseases, such as spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS), share several clinical similarities while differing substantially in etiology, disease onset and progression. Cognitive dysfunction, a clinically relevant non-motor feature in a substantial proportion of ALS patients, has been less frequently investigated in SMA. In this prospective multicenter cross-sectional study, cognitive function was assessed by the Edinburgh Cognitive (and Behavioural) ALS Screen (ECAS) and a German vocabulary test (Wortschatztest, WST) in 34 adult patients with SMA types 2–4 and in 34 patients with ALS. Demographic and clinical parameters were assessed to identify factors that potentially influence cognitive function. While SMA and ALS patients were comparable in the vocabulary test, on average, SMA patients performed better than ALS patients in the cognitive domains of memory, language and executive function. Better cognitive abilities in SMA patients seemed to be related to the early onset, rather than the extent or the duration, of their physical handicap. Future studies should focus on disease-specific cognitive functions in SMA. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. Motor neuron disease: Genetic testing in amyotrophic lateral sclerosis.
- Author
-
Ludolph, Albert C.
- Subjects
- *
MOTOR neuron diseases , *GENETIC testing , *AMYOTROPHIC lateral sclerosis , *ETIOLOGY of diseases , *FRONTOTEMPORAL dementia - Published
- 2017
- Full Text
- View/download PDF
42. Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis.
- Author
-
Rué, Laura, Oeckl, Patrick, Timmers, Mieke, Lenaerts, Annette, van der Vos, Jasmijn, Smolders, Silke, Poppe, Lindsay, de Boer, Antina, Van Den Bosch, Ludo, Van Damme, Philip, Weishaupt, Jochen H., Ludolph, Albert C., Otto, Markus, Robberecht, Wim, and Lemmens, Robin
- Subjects
AMYOTROPHIC lateral sclerosis ,DISEASE progression ,MOTOR neuron diseases ,MOTOR neurons ,SPINAL cord ,CEREBROSPINAL fluid - Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that affects motor neurons in the brainstem, spinal cord and motor cortex. ALS is characterized by genetic and clinical heterogeneity, suggesting the existence of genetic factors that modify the phenotypic expression of the disease. We previously identified the axonal guidance EphA4 receptor, member of the Eph-ephrin system, as an ALS disease-modifying factor. EphA4 genetic inhibition rescued the motor neuron phenotype in zebrafish and a rodent model of ALS. Preventing ligands from binding to the EphA4 receptor also successfully improved disease, suggesting a role for EphA4 ligands in ALS. One particular ligand, ephrin-A5, is upregulated in reactive astrocytes after acute neuronal injury and inhibits axonal regeneration. Moreover, it plays a role during development in the correct pathfinding of motor axons towards their target limb muscles. We hypothesized that a constitutive reduction of ephrin-A5 signalling would benefit disease progression in a rodent model for ALS. We discovered that in the spinal cord of control and symptomatic ALS mice ephrin-A5 was predominantly expressed in neurons. Surprisingly, reduction of ephrin-A5 levels in SOD1
G93A mice accelerated disease progression and reduced survival without affecting disease onset, motor neuron numbers or innervated neuromuscular junctions in symptomatic mice. These findings suggest ephrin-A5 as a modifier of disease progression that might play a role in the later stages of the disease. Similarly, we identified a more aggressive disease progression in patients with lower ephrin-A5 protein levels in the cerebrospinal fluid without modifying disease onset. In summary, we identified reduced expression of ephrin-A5 to accelerate disease progression in a mouse model of ALS as well as in humans. Combined with our previous findings on the role of EphA4 in ALS our current data suggests different contribution for various members of the Eph-ephrin system in the pathophysiology of a motor neuron disease. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
43. Non-invasive ventilation in amyotrophic lateral sclerosis.
- Author
-
Dorst, Johannes and Ludolph, Albert C.
- Abstract
Non-invasive ventilation (NIV) has become an important cornerstone of symptomatic treatment in amyotrophic lateral sclerosis (ALS), improving survival and quality of life. In this review, we summarize the most important recent developments and insights, including evidence of efficacy, indication criteria and time of initiation, ventilation parameters and adaptation strategies, treatment of complicating factors, transition from NIV to invasive ventilation, termination of NIV and end-of-life management. Recent publications have questioned former conventions and guideline recommendations, especially with regard to timing and prognostic factors; therefore, a fresh look and re-evaluation of current evidence is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
44. Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease.
- Author
-
Müller, Kathrin, Andersen, Peter M., Hübers, Annemarie, Marroquin, Nicolai, Volk, Alexander E., Danzer, Karin M., Meitinger, Thomas, Ludolph, Albert C., Strom, Tim M., and Weishaupt, Jochen H.
- Subjects
GENE silencing ,IMMUNOGLOBULINS ,GENETIC code ,GENETIC mutation ,MOTOR neuron diseases ,GENETIC disorders - Published
- 2014
- Full Text
- View/download PDF
45. TDP-43 is intercellularly transmitted across axon terminals.
- Author
-
Feiler, Marisa S., Strobel, Benjamin, Freischmidt, Axel, Helferich, Anika M., Kappel, Julia, Brewer, Bryson M., Deyu Li, Thal, Dietmar R., Walther, Paul, Ludolph, Albert C., Danzer, Karin M., and Weishaupt, Jochen H.
- Subjects
- *
DNA-binding proteins , *AXONS , *AMYOTROPHIC lateral sclerosis , *MOTOR neuron diseases , *OLIGOMERS - Abstract
Transactive response DNA-binding protein 43 kD (TDP-43) is an aggregation-prone prion-like domain-containing protein and component of pathological intracellular aggregates found in most amyotrophic lateral sclerosis (ALS) patients. TDP-43 oligomers have been postulated to be released and subsequently nucleate TDP-43 oligomerization in recipient cells, which might be the molecular correlate of the systematic symptom spreading observed during ALS progression. We developed a novel protein complementation assay allowing quantification of TDP-43 oligomers in living cells. We demonstrate the exchange of TDP-43 between cell somata and the presence of TDP-43 oligomers in microvesicles/ exosomes and show that microvesicular TDP-43 is preferentially taken up by recipient cells where it exerts higher toxicity than free TDP-43. Moreover, studies using microfluidic neuronal cultures suggest both anterograde and retrograde trans-synaptic spreading of TDP-43. Finally, we demonstrate TDP-43 oligomer seeding by TDP-43-containing material derived from both cultured cells and ALS patient brain lysate. Thus, using an innovative detection technique, we provide evidence for preferentially microvesicular uptake as well as both soma-to-soma "horizontal" and bidirectional "vertical" synaptic intercellular transmission and prion-like seeding of TDP-43. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
46. Dynein mutations associated with hereditary motor neuropathies impair mitochondrial morphology and function with age.
- Author
-
Eschbach, Judith, Sinniger, Jérôme, Bouitbir, Jamal, Fergani, Anissa, Schlagowski, Anna-Isabel, Zoll, Joffrey, Geny, Bernard, René, Frédérique, Larmet, Yves, Marion, Vincent, Baloh, Robert H., Harms, Matthew B., Shy, Michael E., Messadeq, Nadia, Weydt, Patrick, Loeffler, Jean-Philippe, Ludolph, Albert C., and Dupuis, Luc
- Subjects
- *
DYNEIN , *GENETIC mutation , *MOTOR neuron diseases , *MITOCHONDRIAL pathology , *SPINAL muscular atrophy , *CHARCOT-Marie-Tooth disease , *NEUROPATHY , *LABORATORY mice - Abstract
Abstract: Mutations in the DYNC1H1 gene encoding for dynein heavy chain cause two closely related human motor neuropathies, dominant spinal muscular atrophy with lower extremity predominance (SMA–LED) and axonal Charcot–Marie–Tooth (CMT) disease, and lead to sensory neuropathy and striatal atrophy in mutant mice. Dynein is the molecular motor carrying mitochondria retrogradely on microtubules, yet the consequences of dynein mutations on mitochondrial physiology have not been explored. Here, we show that mouse fibroblasts bearing heterozygous or homozygous point mutation in Dync1h1, similar to human mutations, show profoundly abnormal mitochondrial morphology associated with the loss of mitofusin 1. Furthermore, heterozygous Dync1h1 mutant mice display progressive mitochondrial dysfunction in muscle and mitochondria progressively increase in size and invade sarcomeres. As a likely consequence of systemic mitochondrial dysfunction, Dync1h1 mutant mice develop hyperinsulinemia and hyperglycemia and progress to glucose intolerance with age. Similar defects in mitochondrial morphology and mitofusin levels are observed in fibroblasts from patients with SMA–LED. Last, we show that Dync1h1 mutant fibroblasts show impaired perinuclear clustering of mitochondria in response to mitochondrial uncoupling. Our results show that dynein function is required for the maintenance of mitochondrial morphology and function with aging and suggest that mitochondrial dysfunction contributes to dynein-dependent neurological diseases, such as SMA–LED. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
47. The modulation of Amyotrophic Lateral Sclerosis risk by Ataxin-2 intermediate polyglutamine expansions is a specific effect
- Author
-
Gispert, Suzana, Kurz, Alexander, Waibel, Stefan, Bauer, Peter, Liepelt, Inga, Geisen, Christof, Gitler, Aaron D., Becker, Tim, Weber, Markus, Berg, Daniela, Andersen, Peter M., Krüger, Rejko, Riess, Olaf, Ludolph, Albert C., and Auburger, Georg
- Subjects
- *
AMYOTROPHIC lateral sclerosis , *GLUTAMINE , *NEURODEGENERATION , *CEREBELLAR ataxia , *PARKINSON'S disease , *MOTOR neuron diseases , *DOPA - Abstract
Abstract: Full expansions of the polyglutamine domain (polyQ≥34) within the polysome-associated protein ataxin-2 (ATXN2) are the cause of a multi-system neurodegenerative disorder, which usually presents as a Spino-Cerebellar Ataxia and is therefore known as SCA2, but may rarely manifest as Levodopa-responsive Parkinson syndrome or as motor neuron disease. Intermediate expansions (27≤polyQ≤33) were reported to modify the risk of Amyotrophic Lateral Sclerosis (ALS). We have now tested the reproducibility and the specificity of this observation. In 559 independent ALS patients from Central Europe, the association of ATXN2 expansions (30≤polyQ≤35) with ALS was highly significant. The study of 1490 patients with Parkinson''s disease (PD) showed an enrichment of ATXN2 alleles 27/28 in a subgroup with familial cases, but the overall risk of sporadic PD was unchanged. No association was found between polyQ expansions in Ataxin-3 (ATXN3) and ALS risk. These data indicate a specific interaction between ATXN2 expansions and the causes of ALS, possibly through altered RNA-processing as a common pathogenic factor. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
48. In vivo quantification of spinal and bulbar motor neuron degeneration in the G93A-SOD1 transgenic mouse model of ALS by T 2 relaxation time and apparent diffusion coefficient
- Author
-
Niessen, Heiko G., Angenstein, Frank, Sander, Kerstin, Kunz, Wolfram S., Teuchert, Marko, Ludolph, Albert C., Heinze, Hans-Jochen, Scheich, Henning, and Vielhaber, Stefan
- Subjects
- *
MAGNETIC resonance imaging , *AMYOTROPHIC lateral sclerosis , *MOTOR neuron diseases , *TRANSGENIC mice - Abstract
Abstract: Magnetic resonance imaging (MRI) has provided important information in characterizing amyotrophic lateral sclerosis (ALS) in humans and in animal models. A frequently used animal model to study mechanisms of pathogenesis and the efficacy of drugs in ALS is a transgenic mouse over-expressing the human mutated G93A-superoxide dismutase 1 (G93A-SOD1). In our study, we applied MRI to find suitable progression markers, which can be used to monitor the development of ALS and to evaluate therapeutic approaches at early stages of the disease. Therefore, we generated parameter maps of the spin–spin relaxation time (T 2) and the apparent diffusion coefficient (ADC) starting at day 70 after birth, i.e., before motor scores decline around day 90. Depending on the progression of the disease, G93A-SOD1 mice showed significantly increased values of T 2 in the brain stem motor nuclei Nc. V (trigeminal nucleus), VII (facial nucleus), and XII (hypoglossal nucleus), and spinal cord compared to non-transgenic wild-type mice and transgenic mice over-expressing the non-mutated wild-type human SOD1 (tg-SOD1). Similar effects in these motor nuclei were revealed by ADC mapping. Furthermore, in the upper spinal cord, a dorsal–ventral difference with significantly higher T 2 values in the ventral part was demonstrated by T 2 mapping. While both T 2 and ADC might prove useful as progression markers and enable the longitudinal non-invasive evaluation of ALS in G93A-SOD1 mice, the potential is limited by age-dependent effects in case of ADC mapping. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
49. Frequency of a tau genotype in amyotrophic lateral sclerosis
- Author
-
Münch, Christoph, Prechter, Florian, Xu, Renshi, Linke, Peter, Prudlo, Johannes, Kuzma, Magdalena, Kwiecinski, Hubert, Ludolph, Albert C., and Meyer, Thomas
- Subjects
- *
AMYOTROPHIC lateral sclerosis , *GENETIC polymorphisms , *GENETIC research , *MOTOR neuron diseases - Abstract
Abstract: We investigated the susceptibility of the dinucleotide polymorphism A0 in the tau gene to amyotrophic lateral sclerosis (ALS). In 416 unrelated patients with ALS and 242 control subjects the A0/A0 genotype was not associated with the pooled sample of ALS cases. Subgroup analysis revealed that in sporadic ALS the A0 polymorphism was significantly overrepresented. There was no association of the A0/A0 genotype with the age and site of disease onset or the presence of dementia. The studied tau genotype may contribute to the multifactorial genetic background of ALS. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
50. SQSTM1/p62 variants in 486 patients with familial ALS from Germany and Sweden.
- Author
-
Yilmaz, Rüstem, Müller, Kathrin, Brenner, David, Volk, Alexander E., Borck, Guntram, Hermann, Andreas, Meitinger, Thomas, Strom, Tim M., Danzer, Karin M., Ludolph, Albert C., Andersen, Peter M., and Weishaupt, Jochen H.
- Subjects
- *
AMYOTROPHIC lateral sclerosis , *PROTEOLYSIS , *MOTOR neuron diseases - Abstract
Several studies reported amyotrophic lateral sclerosis (ALS)-linked mutations in TBK1 , OPTN , VCP , UBQLN2 , and SQSTM1 genes encoding proteins involved in autophagy. SQSTM1 was originally identified by a candidate gene approach because it encodes p62, a multifunctional protein involved in protein degradation both through proteasomal regulation and autophagy. Both p62 and optineurin (encoded by OPTN) are direct interaction partners and substrates of TBK1, and these 3 proteins form the core of a genetic and functional network that may connect autophagy with ALS. Considering the molecular and conceptual relevance of the TBK1 / OPTN / SQSTM1 "triangle," we here performed a targeted screen for SQSTM1 variants in 486 patients with familial ALS from Germany and Sweden by analyzing whole-exome sequencing data. We report 9 novel and 5 previously reported rare variants in SQSTM1 and discuss the current evidence for SQSTM1 as a primary disease gene for ALS. We conclude that the evidence for causality remains vague for SQSTM1 and is weaker than for the other autophagy genes, for example, TBK1 and OPTN. • Fourteen rare variants were found in SQSTM1 in our familial ALS patient cohort. • Nine variants were novel, whereas 5 were previously reported. • The variant c.98C>T (p.Ala33Val) did not cosegregate with the disease. • Rare SQSTM1 variants were not enriched in patients in comparison to the controls. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.